Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 5/20 | 0.40 |
| ▸ | CTSK | P43235 | 5/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8011913 | 0.90 | NSD2 (0.46) | NSD2L3MBTL1NAMPTCA1CA2 | |
| SCHEMBL20096072 | 0.85 | NSD2 (0.44) | NSD2L3MBTL1NAMPTCA1CA2 | |
| SCHEMBL31431170 | 0.85 | NSD2 (0.44) | NSD2L3MBTL1NAMPTCA1CA2 | |
| SCHEMBL20095414 | 0.84 | NSD2 (0.43) | NSD2L3MBTL1NAMPTCA1CA2 | |
| SCHEMBL22829000 | 0.83 | NSD2 (0.47) | NSD2L3MBTL1NAMPTCA1CA2 | |
| SCHEMBL6928939 | 0.82 | TRPA1 (0.54) | NSD2L3MBTL1NAMPTGAAKDM4A | |
| SCHEMBL3396307 | 0.82 | NSD2 (0.46) | NSD2L3MBTL1NAMPTCA1CA2 | |
| SCHEMBL16104792 | 0.81 | KDM4A (0.47) | L3MBTL1NAMPTCA1CA2GAA | |
| SCHEMBL22828999 | 0.81 | ALDH1A1 (0.48) | NSD2L3MBTL1TSHR | |
| SCHEMBL23274113 | 0.80 | RXRA (0.48) | NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654852-B2 | Antibiotics and methods of using same | THE BROAD INSTITUTE, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190240203-A1 | NOVEL ANTIBIOTICS AND METHODS OF USING SAME | THE BROAD INSTITUTE, INC. (US) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240203-A1 | NOVEL ANTIBIOTICS AND METHODS OF USING SAME | NRDC, TLR6, PEPD | NSD2 3960/4885L3MBTL1 2861/4885NAMPT 1167/4885 |
| US-10654852-B2 | Antibiotics and methods of using same | NRDC, PEPD, TREH | NSD2 3577/4885L3MBTL1 2798/4885NAMPT 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.